CRUK and Cambridge precision cancer diagnostics spinout Inivata has secured $25m from NeoGenomics as part of a deal that includes an acquisition option.
Inivata, a UK-based cancer diagnostics spinout of University of Cambridge and Cancer Research UK, yesterday received $25m from cancer diagnostics service provider NeoGenomics in a strategic deal that includes an acquisition option.
Founded in 2014, Inivata develops liquid biopsy tests under the InVision brand that provide cancer diagnoses based on genomic markers indicative of circulating tumour DNA.
Its flagship product, InVisionFirst-Lung, tests patients for advanced non-small cell lung cancer, a subtype responsible for an estimated 80% to 85%…
